Page 33 - Quest Diagnostics News Today

StockNews.com cut shares of Quest Diagnostics (NYSE:DGX – Free Report) from a buy rating to a hold rating in a research report released on Friday morning. DGX has been the subject of a number of other research reports. Barclays lifted their price target on shares of Quest Diagnostics from $138.00 to $144.00 and gave the […]

StockNews.com lowered shares of Quest Diagnostics (NYSE:DGX – Free Report) from a buy rating to a hold rating in a research report released on Friday. Other research analysts also recently issued research reports about the stock. Truist Financial increased their price objective on shares of Quest Diagnostics from $145.00 to $150.00 and gave the company […]

Transaction is part of wide-ranging collaboration to combine Quests oncology expertise and scale with PathAIs AI and digital pathology innovations to speed diagnosis, improve quality and reduce...

Transaction is part of wide-ranging collaboration to combine Quest's oncology expertise and scale with PathAI's AI and digital pathology innovations to speed diagnosis, improve quality and reduce costsSECAUCUS, NJ and BOSTON, MA / ACCESSWIRE / May 6, 2024 / Quest Diagnostics (NYSE:DGX), a leader in diagnostic inform...

First Trust Direct Indexing L.P. lifted its position in shares of Quest Diagnostics Incorporated (NYSE:DGX – Free Report) by 10.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,232 shares of the medical research company’s stock after purchasing an additional […]

WESTPORT, Conn., May 03, 2024 (GLOBE NEWSWIRE) -- HMG Strategy, the World’s #1 platform for enabling technology executives to reimagine the enterprise...

02.05.2024 - NORTHAMPTON, MA / ACCESSWIRE / May 2, 2024 / Quest Diagnostics: At a glance:Quest worked with St. James Health in Newark to provide no-cost Blueprint for Wellness screenings during a Choose Healthy Life event to celebrate expansion of Newark, ... Seite 1

Laboratory tests used by millions of Americans are soon to be classified as medical devices, and as such be regulated by the U.S. Food and Drug Administration, the agency announced Monday. Laboratory tests used by millions of Americans are soon to be classified as medical devices, and as such be regulated by the U.S. Food and Drug Administration, the agency announced Monday.

The Food and Drug Administration has finalized a rule to regulate medical tests that have long escaped oversight

Quest Diagnostics Inc. and Pathai Inc. established a forward-looking deal with multiple components and room for growth. The collaboration includes Quest’s acquisition of Pathai Diagnostics – the division that provides anatomic and digital pathology laboratory services – and licensing of Pathai’s Aisight digital pathology image management system. The companies also said they may work together on development of Pathai’s algorithm products and that Quest will be a preferred provider for P...